Efficacy of Subcutaneous Semaglutide Compared to Placebo For Weight Loss in Obese, Non-diabetic Adults: A Systematic Review & Meta-Analysis
Int J Clin Pharm 2022; online ahead of print DOI: 10.1007/s11096-022-01428-1
This systematic review and meta-analysis quantified the efficacy of subcutaneous semaglutide compared to placebo for obesity. The final analysis included four randomised controlled trials, encompassing 2,882 participants with body mass index (BMI) of 27 or more.
Pooled estimate of the mean difference versus placebo was −11.62 kg, with a reduction in mean waist circumference of –9.16 cm. Semaglutide efficacy, safety, and affordability validate the drug as a favourable approach to weight loss compared to available stimulant-based therapies.